Sorafenib inhibits transforming growth factor β1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes

Sorafenib inhibits transforming growth factor β1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes

Epithelial-mesenchymal transition (EMT) is a physiological process that has been recognized to occur during the progression of an increasingly large number of human diseases, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. The activation of transforming growth factor β (TGF-β) sig...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Yue‐Lei Chen, Jing Lv, Xiaolei Ye, Mingyu Sun, Qin Xu, Chenghai Liu, Lihua Min, Huiping Li, Ping Liu, Xiaoyan Ding
Hōputu:	Artigo
Reo:	Ingarihi
I whakaputaina:	2011
Urunga tuihono:	https://doi.org/10.1002/hep.24254 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.24254
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Sorafenib Inhibits Epithelial-Mesenchymal Transition through an Epigenetic-Based Mechanism in Human Lung Epithelial Cells
mā: Zhang, Juyong, me ētahi atu.
I whakaputaina: (2013)

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
mā: Tomoyuki Nagai, me ētahi atu.
I whakaputaina: (2011)

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
mā: Yanru Deng, me ētahi atu.
I whakaputaina: (2016)

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
mā: Deng, Yan-Ru, me ētahi atu.
I whakaputaina: (2016)

The hepatocyte-specifically expressed lnc-HSER alleviates hepatic fibrosis by inhibiting hepatocyte apoptosis and epithelial-mesenchymal transition
mā: Zhang, Kun, me ētahi atu.
I whakaputaina: (2019)

The hepatocyte-specifically expressed lnc-HSER alleviates hepatic fibrosis by inhibiting hepatocyte apoptosis and epithelial-mesenchymal transition
mā: Kun Zhang, me ētahi atu.
I whakaputaina: (2019)

Histone deacetylase inhibition suppresses the transforming growth factor β1-induced epithelial-to-mesenchymal transition in hepatocytes
mā: Aki Kaimori, me ētahi atu.
I whakaputaina: (2010)

Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial–mesenchymal transition and fibroblast activation
mā: Yi‐Lang Chen, me ētahi atu.
I whakaputaina: (2013)

Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
mā: Chen, Weibo, me ētahi atu.
I whakaputaina: (2019)

PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial-mesenchymal transition
mā: Liu, Hongyu, me ētahi atu.
I whakaputaina: (2019)

Autophagy regulates hepatocyte identity and epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions promoting Snail degradation
mā: Germana Grassi, me ētahi atu.
I whakaputaina: (2015)

SYNCRIP Modulates the Epithelial-Mesenchymal Transition in Hepatocytes and HCC Cells
mā: Riccioni, Veronica, me ētahi atu.
I whakaputaina: (2022)

Hypoxia Stimulates Hepatocyte Epithelial to Mesenchymal Transition by Hypoxiainducible Factor- and Transforming Growth Factor-β-dependent Mechanisms
mā: Copple, Bryan L.
I whakaputaina: (2010)

Melatonin Inhibits Transforming Growth Factor-β1-Induced Epithelial–Mesenchymal Transition in AML12 Hepatocytes
mā: Kim, Jung-Yeon, me ētahi atu.
I whakaputaina: (2019)

Regorafenib reverses <scp>HGF</scp>‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
mā: Weibo Chen, me ētahi atu.
I whakaputaina: (2018)

Sorafenib Ameliorates Renal Fibrosis through Inhibition of TGF-β-Induced Epithelial-Mesenchymal Transition
mā: Jia, Lining, me ētahi atu.
I whakaputaina: (2015)

Hepatocytes Do Not Undergo Epithelial-Mesenchymal Transition in Liver Fibrosis in Mice
mā: Taura, Kojiro, me ētahi atu.
I whakaputaina: (2010)

Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice
mā: Kojiro Taura, me ētahi atu.
I whakaputaina: (2009)

Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-β-dependent mechanisms
mā: Bryan L. Copple
I whakaputaina: (2010)

Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial–mesenchymal transition and fibroblast activation
mā: Chen, Y-L, me ētahi atu.
I whakaputaina: (2013)

Dual role of RACK1 in airway epithelial mesenchymal transition and apoptosis
mā: Pu, Yue, me ētahi atu.
I whakaputaina: (2020)

A Novel Mechanism by which Hepatocyte Growth Factor Blocks Tubular Epithelial to Mesenchymal Transition
mā: Junwei Yang, me ētahi atu.
I whakaputaina: (2004)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
I whakaputaina: (2022)

FZD5 prevents epithelial-mesenchymal transition in gastric cancer
mā: Dong, Dan, me ētahi atu.
I whakaputaina: (2021)

MicroRNA-101 inhibits renal tubular epithelial-to-mesenchymal transition by targeting TGF-β1 type I receptor
mā: Wang, Qinglan, me ētahi atu.
I whakaputaina: (2021)

Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial–mesenchymal transition
mā: Tian, Chuntao, me ētahi atu.
I whakaputaina: (2022)

Hepatitis C Virus Induces Epithelial-Mesenchymal Transition in Primary Human Hepatocytes
mā: Bose, Sandip K., me ētahi atu.
I whakaputaina: (2012)

Fibroblasts Derive from Hepatocytes in Liver Fibrosis via Epithelial to Mesenchymal Transition
mā: Michael Zeisberg, me ētahi atu.
I whakaputaina: (2007)

Hepatitis C Virus Induces Epithelial-Mesenchymal Transition in Primary Human Hepatocytes
mā: Sandip K. Bose, me ētahi atu.
I whakaputaina: (2012)

Human lens epithelial cell apoptosis and epithelial to mesenchymal transition in femtosecond laser-assisted cataract surgery
mā: Sun, Wei, me ētahi atu.
I whakaputaina: (2018)

C-phycocyanin inhibits epithelial-to-mesenchymal transition in Caski cells
mā: Ji, Huanhuan, me ētahi atu.
I whakaputaina: (2020)

KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition
mā: Hu, Bo, me ētahi atu.
I whakaputaina: (2019)

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells
mā: Liao, Li-Zhu, me ētahi atu.
I whakaputaina: (2020)

Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells
mā: Xu, Gui-Li, me ētahi atu.
I whakaputaina: (2020)

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells
mā: Li-Zhu Liao, me ētahi atu.
I whakaputaina: (2020)

Aneuploidy, oncogene amplification and epithelial to mesenchymal transition define spontaneous transformation of murine epithelial cells
mā: Padilla-Nash, Hesed M., me ētahi atu.
I whakaputaina: (2013)

Salvianolic acid B prevents epithelial-to-mesenchymal transition through the TGF-β1 signal transduction pathway in vivo and in vitro
mā: Qinglan Wang, me ētahi atu.
I whakaputaina: (2010)

ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression
mā: Lahsnig, C, me ētahi atu.
I whakaputaina: (2008)

Murine Cirrhosis Induces Hepatocyte Epithelial Mesenchymal Transition and Alterations in Survival Signaling Pathways
mā: Nitta, Takashi, me ētahi atu.
I whakaputaina: (2008)

Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways
mā: Takashi Nitta, me ētahi atu.
I whakaputaina: (2008)